National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Noopur Raje
MD
Mass General Brigham Cancer Institute, Boston, Massachusetts
Director, Center for Multiple Myeloma and Plasma Cell Disorders
Harvard Medical School, Boston, Massachusetts
Rita Kelley Chair in Oncology, Professor of Medicine
Moderator
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
TARGET AUDIENCE This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare professionals involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
Consider published research findings and other clinical factors affecting the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
Assess available and emerging research data with B-cell maturation antigen (BCMA)-directed and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms.
Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators (CELMoDs) to identify patients with R/R MM who are optimal candidates for CELMoD-containing regimens.
Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM.
Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients.
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR Dr Orlowski — Advisory Committees and ConsultingAgreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma AG, Regeneron Pharmaceuticals Inc; Data and SafetyMonitoring Boards/Committees: Sanofi.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.
Release date: October 9, 2026 Expiration date: October 9, 2027
Dr Raje
Mateos MV et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3. ASH 2025;Abstract LBA-6.
Mian HS et al. Cevostamab plus pomalidomide (pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM): Phase I dose-expansion results from the CAMMA 1 study. IMS 2025;Abstract OA-14.
Mina R et al. Talquetamab-daratumumab in relapsed or refractory myeloma.N Engl J Med 2026;395(7):671-83. Abstract
Touzeau C et al. Teclistamab in multiple myeloma with one to three previous lines of therapy.N Engl J Med 2026;395(5):440-53. Abstract
Dr Orlowski
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma.N Engl J Med 2024;391(5):408-21. Abstract
Hungria V et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): Updated overall survival analysis from a global, randomised, open-label, phase 3 trial.Lancet Oncol 2025;26(8):1067-80. Abstract
Mateos MV et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.Blood Adv 2025;9(22):5708-19. Abstract
Dr Dimopoulos
Bal S et al. Arlocabtagene autoleucel: A GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.Blood 2026;148(10):1240-50. Abstract
Dimopoulos MA et al. Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial. EHA 2026;Abstract LB5004.
Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.Future Oncol 2025;21(14):1761-9. Abstract
Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies for Multiple Myeloma — What Clinicians Want To Know
A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting
Program Schedule — Central Time Friday, December 11, 2026 6:30 PM – 7:00 PM — Registration and Dinner 7:00 PM – 9:00 PM — Educational Meeting
Location Sheraton New Orleans Hotel 500 Canal Street New Orleans, Louisiana Hotel Phone: (504) 525-2500
Meeting Room Napoleon Ballroom C/D — Third floor
No registration fee is charged for this event.Preregistration is required for in-person attendance in New Orleans as seating is limited.
Faculty
Adam D Cohen
MD
Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Professor of Medicine (Hematology-Oncology), Director, Myeloma Immunotherapy, Co-Director, Amyloidosis Program
Faculty
Meletios-Athanasios (Thanos) C Dimopoulos
MD
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Suzanne Trudel
MD
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Consultant
University of Toronto, Ontario, Canada
Bloom-Reece Professorship in Multiple Myeloma, Professor of Medicine
Ontario Cancer Institute, Toronto, Ontario, Canada
Clinician Scientist
Moderator
Natalie S Callander
MD
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Professor of Medicine,
Director, Myeloma Clinical and Cellular Therapy Program
This activity is supported by educational grants from Genentech, a member of the Roche Group,andGSK.
Join us on Friday, December 11th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).
Topics to Be Discussed
Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)
Ocular Toxicities and Other Tolerability Considerations with ADCs for MM
Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management
Target Audience This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).
Learning Objectives At the conclusion of this activity, participants should be able to
Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for MM to facilitate their integration into management algorithms.
Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
Implement a plan of care to recognize and manage the toxicities associated with bispecific antibodies and ADCs commonly used for MM in order to maintain patient quality of life and time on treatment.
Assess available research data with BCMA-directed bispecific antibodies for patients with relapsed/refractory (R/R) MM, and appreciate the clinical role of these agents.
Recall recently presented clinical trial results establishing the definitive efficacy of BCMA-directed bispecific antibody therapy in combination with anti-CD38 monoclonal antibody therapy for patients with R/R MM, and integrate this novel therapeutic strategy into management algorithms.
Recall available data with novel bispecific antibody- and ADC-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.
CE Credit CME credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.
FACULTY Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, SwixxBiopharma, Takeda Pharmaceutical Company Limited. Dr Trudel — Advisory Committees: AstraZeneca Pharmaceuticals LP, GSK, Janssen Biotech Inc, Kite, A Gilead Company, Opna Bio, Pfizer Inc, Sanofi; ConsultingAgreements: GSK; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Pfizer Inc, Roche Laboratories Inc. Additional faculty to be announced.
MODERATOR Dr Callander has no relevant financial relationships to disclose.
Research To Practice CME Planning Committee Members, Staff and Reviewers Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.
Sheraton New Orleans Hotel 500 Canal Street New Orleans, LA 70130 Hotel Phone: (504) 525-2500
Meeting Room Napoleon Ballroom C/D — Third floor
Directions The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.
Program slides will be made available prior to the start of the session.
Registration to attend virtually is open to all professionals.
Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
No registration fee is charged for this event. Preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2026 ASH Annual Meeting.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
Data + Perspectives: Investigators Discuss the Optimal Management of Relapsed/Refractory Multiple Myeloma
A CME-Accredited Satellite Symposium During the Society of Hematologic Oncology 2026 Annual Meeting
Program Schedule — Central Time Wednesday, September 9, 2026 11:56 AM – 12:56 PM Educational lunch meeting
Location George R Brown Convention Center 1001 Avenida de las Americas Houston, Texas Phone: (713) 853-8000
Meeting Room Level 3 in Grand Ballroom B (Theater Room 2)
No registration fee. Preregistration is recommended for in-person attendance in Houston as seating is limited.
Faculty
Meletios-Athanasios (Thanos) C Dimopoulos
MD
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Noopur Raje
MD
Mass General Brigham Cancer Institute, Boston, Massachusetts
Director, Center for Multiple Myeloma and Plasma Cell Disorders
Harvard Medical School, Boston, Massachusetts
Rita Kelley Chair in Oncology, Professor of Medicine
Moderator
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.
Join us on Wednesday, September 9th from 11:56 AM to 12:56 PM central time (12:56 PM to 1:56 PM eastern time).
Educational Lunch Meeting
In-person attendees, please check in 15 minutes before the start of the meeting.
Module 1: Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies for MM
Available efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab and the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated MM; optimal incorporation into current management algorithms
Published findings from the Phase III MajesTEC-3 trial supporting the recent FDA approval of teclistamab in combination with subcutaneous daratumumab for patients with R/R MM after ≥1 prior line of treatment
Positive findings from published (MajesTEC-9) and emerging (MagnetisMM-5) Phase III studies evaluating BCMA-targeted bispecific antibodies as monotherapy in earlier lines of treatment
Recently presented results of the Phase III MonumenTAL-3 trial of talquetamab combined with daratumumab with and without pomalidomide for R/R MM after ≥1 prior line of therapy; potential role of this approach
Emerging positive findings from and implications of the Phase III MonumenTAL-6 trial of talquetamab in combination with teclistamab or pomalidomide after 1 to 4 prior lines of therapy
Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab for R/R MM; ongoing Phase III CEVOLUTION trial combining cevostamab with pomalidomide and dexamethasone
MODULE 2: Utility of Antibody-Drug Conjugates for R/R MM
Mechanism of action and structural components of belantamab mafodotin
Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM
Extended efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7
FDA approval and current role of belantamab mafodotin/bortezomib/dexamethasone in the management of R/R MM
Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events, including ocular toxicities
Ongoing studies attempting to further elucidate the role of belantamab mafodotin for MM
MODULE 3: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) and Other Promising Novel Agents and Strategies for R/R MM
Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs
Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
Recently presented data from the Phase III SUCCESSOR-2 trial assessing mezigdomide/carfilzomib/dexamethasone versus carfilzomib/dexamethasone for R/R MM
Ongoing FDA review of new drug applications for iberdomide in combination with daratumumab/dexamethasone and mezigdomide in combination with carfilzomib/dexamethasone for patients with R/R MM, the former with priority review status; potential role of these regimens
Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role
Rationale for the evaluation of chimeric antigen receptor (CAR) T-cell platforms with novel targets or manufacturing processes for R/R MM
Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA Regenerative Medicine Advanced Therapy Designation and ongoing evaluation in the QUINTESSENTIAL and QUINTESSENTIAL-2 studies
Other promising novel strategies in clinical development for patients with R/R MM
Target Audience This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists and other healthcare professionals involved in the treatment of multiple myeloma.
Learning Objectives Upon completion of this activity, participants should be able to
Consider published research findings and other clinical factors affecting the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
Assess available and emerging research data with B-cell maturation antigen (BCMA)-directed and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into current clinical algorithms.
Recall recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research efforts evaluating cereblon E3 ligase modulators (CELMoDs) in order to identify patients with R/R MM who are optimal candidates for CELMoD-containing regimens.
Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with R/R MM.
Recall available data with novel agents and strategies currently under investigation for R/R MM, and discuss clinical trial participation with eligible patients.
CE Credit CME credit information will be given to each participant as part of the meeting course materials.
Accreditation Statement Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
MODERATOR Dr Orlowski — Advisory Committees and ConsultingAgreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma, Regeneron Pharmaceuticals Inc; Data and SafetyMonitoring Boards/Committees: Sanofi.
EDITOR Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
Research To Practice CME Planning Committee Members, Staff and Reviewers Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.
George R Brown Convention Center 1001 Avenida de las Americas Houston, TX 77010 Phone: (713) 853-8000
Meeting Room Level 3 in Grand Ballroom B (Theater Room 2)
Map
This event has passed.
Thank you for your interest in our CME program. Online registration for the in-person event is now closed.SEATS ARE STILL AVAILABLE FOR THE SESSION. The onsite registration desk will open 15 minutes prior to the session start time. If you are interested in attending, please visit the registration desk outside Grand Ballroom B, Theater Room 2 at the George R Brown Convention Center, where the SOHO 2026 Annual Meeting is taking place.
Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
NOTICE: Registration for this event is separate from registration for the SOHO 2026 Annual Meeting. Attendees must be registered for the SOHO Annual Meeting to participate in satellite symposia.
Consensus or Controversy?: Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Hans Lee
MD
Sarah Cannon Research Institute, Nashville, Tennessee
Director, Multiple Myeloma Research
Faculty
Noopur Raje
MD
Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Director, Center for Multiple Myeloma,
Rita Kelley Chair in Oncology
Harvard Medical School Boston, Massachusetts
Professor of Medicine
Moderator
Joseph Mikhael
MD, MEd
City of Hope Cancer Center, Phoenix, Arizona
Professor, Clinical Genomics and Therapeutics,
Translational Genomics Research Institute (TGen)
International Myeloma Foundation, Phoenix, Arizona
Chief Medical Officer
TARGET AUDIENCE This program is intended for hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of multiple myeloma (MM).
PURPOSE STATEMENT By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.
LEARNING OBJECTIVES
Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) MM.
Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended.
Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
Recall recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
Analyze the mechanism of action of, published efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators, and use this information to prepare for the potential clinical availability of these agents for patients with R/R MM.
Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly administered to patients with R/R MM.
ACCREDITATION, SUPPORT AND CREDIT STATEMENT In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) Successful completion of this CME activity which includes participation in the evaluation components, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
NURSING CONTINUING PROFESSIONAL DEVELOPMENT Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours and 1.25 contact hours in the area of pharmacology.
ONCC/ILNA CERTIFICATION INFORMATION The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/Relapsed-RefractoryMM/Sep4/ILNA.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
CONTINUING PHARMACY EDUCATION Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA0007322-0000-25-046-H01-P
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy
PRIVACY POLICY Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
DISCLOSURE & FINANCIAL RELATIONSHIPS POLICY Medical Learning Institute Inc (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Meletios-Athanasios (Thanos) C Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece
Hans Lee, MD Director, Multiple Myeloma Research Sarah Cannon Research Institute Nashville, Tennessee
Consulting Agreements: Alexion Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Alexion Pharmaceuticals, Amgen Inc, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc.
Noopur Raje, MD Director, Center for Multiple Myeloma Rita Kelley Chair in Oncology Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts
Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi.
SURVEY PARTICIPANTS — Natalie S Callander, MD, has no relevant financial relationships to disclose. Thomas Martin, MD — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson, Sanofi; Data and Safety Monitoring Boards/Committees: Lilly. Surbhi Sidana, MD — Advisory Committees and Consulting Agreements: AbbVie Inc, Arcellx, BioLineRx, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol Myers Squibb, Janssen Biotech Inc, Magenta Therapeutics, Novartis; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb.
MODERATOR Joseph Mikhael, MD, MEd Professor, Clinical Genomics and Therapeutics Translational Genomics Research Institute (TGen) City of Hope Cancer Center Chief Medical Officer International Myeloma Foundation Phoenix, Arizona
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
Release date: October 2, 2025 Expiration date: October 2, 2026
After completing the post-test, learners may download and review the answers here in order to identify further areas of study.
Dr Raje
Agha ME et al. CARTITUDE-2 cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. EHA 2022;Abstract S185.
Bal S et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). ASH 2024;Abstract 922.
Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.
Frigault MJ et al. Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. ASH 2023;Abstract 1023.
Hillengass J et al. Ciltacabtagene autoleucel in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 biological correlative analyses and updated clinical data. EHA 2022;Abstract P959.
Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. International Myeloma Society 2024;Abstract OA-65.
Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma.N Engl J Med 2023;388(11):1002-14. Abstract
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma.N Engl J Med 2023;389(4):335-47. Abstract
Usmani S et al. KarMMa-2 cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. ASH 2022;Abstract 361.
Voorhees PM et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7507.
Dr Lee
Bahlis NJ et al. Talquetamab (tal) + daratumumab (dara) + pomalidomide (pom) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the phase 1b TRIMM-2 study. International Myeloma Society (IMS) 2024;Abstract OA-01.
Baljevic M et al. Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2025;Abstract 7527.
Banerjee R et al. IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels.Blood Adv 2025;[Online ahead of print]. Abstract
Bumma N et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma.J Clin Oncol 2024;42(22):2702-12. Abstract
Chari A et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab.Clin Lymphoma Myeloma Leuk 2024;24(10):665-93. Abstract
Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1.Blood 2022;140(Suppl 1):384-7. Abstract
Chari A et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma.N Engl J Med 2022;387(24):2232-44. Abstract
Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma.N Engl J Med 2025;392(2):138-49. Abstract
Cohen Y et al. Talquetamab (tal) + teclistamab (tec) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated phase 1B results from RedirecTT-1 with >1 year of follow-up. IMS 2024;Abstract OA-03.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Kowalski A et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies.Blood Adv 2025;[Online ahead of print]. Abstract
Kowalski A et al. Tocilizumab prophylaxis for patients with relapsed or refractory multiple myeloma treated with teclistamab, elranatamab or talquetamab. ASH 2024;Abstract 932.
Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results.Nat Med 2023;29(9):2259-67. Abstract
Narayan N et al. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma.JAAD Case Rep 2022;31:66-8. Abstract
Raab MS et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) trial. ASH 2024;Abstract 493.
Reese M et al. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol 2024;15:1424925. Abstract
Richter J et al. Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. ASH 2024;Abstract 1021.
Rifkin R et al. Optec: A phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM): Updated results. ASH 2024;Abstract 4753.
Rodriguez-Otero P et al. GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review.Blood Cancer J 2024;14(1):24. Abstract
Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.
Prof Dimopoulos
Bjorklund CC et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.Leukemia 2020;34(4):1197-1201. Abstract
Charliński G et al. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma.Cancers (Basel) 2021;13(18):4666. Abstract
Dimopoulos MA et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.Nat Rev Clin Oncol 2025;22(9):680-700. Abstract
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract
Dimopoulos MA et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract LB3440.
Gay F et al. Iberdomide maintenance after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. EHA 2024:Abstract P958.
Hartley-Brown MA et al. Mezigdomide — A novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma.Cancers (Basel) 2024;16(6):1166. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(5):393-407. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.
Hungria VTM et al. Characterization and management of ocular events in patients (Pts) treated with belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study. International Myeloma Society (IMS) 2024;Abstract P-396.
Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.Int J Hematol 2016;104(3):293-9. Abstract
Liu Y et al. Targeting Ikaros and Aiolos: Reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.Expert Rev Hematol 2024;17(8):445-65. Abstract
Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1/2 trial.Lancet Haematol 2022;9(11):e822-32. Abstract
Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). EHA 2021;Abstract S187.
Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the dose-expansion phase of the CC-220-MM-001 trial.Blood 2021;138(Suppl 1):162. Abstract
Mateos M-V et al. Results from DREAMM-7 a randomized phase 3 study of belantamab mafodotin + bortezomib, and dexamethasone vs daratumumab + bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. EHA 2024;Abstract S214.
Offidani M et al. Belantamab mafodotin for the treatment of multiple myeloma: An overview of the clinical efficacy and safety.Drug Des Devel Ther 2021;15:2401-15. Abstract
Quach H et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. IMS 2024;Abstract P-413.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma.N Engl J Med 2023;389(11):1009-22. Abstract
Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.
Terpos E et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events.Am J Hematol 2025;100(10):1839-50. Abstract
Trudel S et al. Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. ASCO 2025;Abstract 7515.
Trudel S et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). ASCO 2024;Abstract LBA105.
van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study. ASH 2023;Abstract 208.
SOHO 2025
Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
Customize the selection of first-line therapy for newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
Appreciate clinical trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory MM.
Evaluate published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
Assess available findings with available and investigational bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
Review recently presented research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential role of this form of treatment in clinical practice.
Recall available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in relevant clinical trials.
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) CME credit is no longer available for this issue.
PRIVACY POLICY Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/MM/Video/CME.
CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Meletios-Athanasios (Thanos) C Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece
Robert Z Orlowski, MD, PhD Florence Maude Thomas Cancer Research Professor Department of Lymphoma and Myeloma Professor, Department of Experimental Therapeutics Vice Chair, Myeloma Translational Research Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas
Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Stock Options — Private Companies: Asylia Therapeutics Inc.
MODERATOR —Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from GSK and Sanofi.
Release date: June 2025 Expiration date: June 2026
Ailawadhi S et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses.Blood 2024;144(23):2389-401. Abstract
Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study.Blood 2025;145(3):300-10. Abstract
Bertamini L et al. Circulating tumor cells as a biomarker to identify high-risk transplant eligible myeloma patients treated with bortezomib, lenalidomide and dexamethasone with or without daratumumab during induction/consolidation, and lenalidomide with or without daratumumab during maintenance: Results from the Perseus study. ASH 2024;Abstract 487.
Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma.N Engl J Med 2025;392(2):138-49. Abstract
Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma.N Engl J Med 2025;392(18):1777-88. Abstract
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma.N Engl J Med 2024;391(5):408-21. Abstract
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(17):1597-609. Abstract
Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(5):393-407. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.
Jurgens EM et al. Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis.J Clin Oncol 2025;43(5):498-504. Abstract
Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial.Nat Med 2024;30(8):2235-41. Abstract
Mai EK et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: Final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43(11):1279-88. Abstract
Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. IMS 2024;Abstract OA-65.
Pasquini MC et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival.J Clin Oncol 2024;42(23):2757-68. Abstract
Prince HM et al. MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. ASH 2024;Abstract 4738.
Rasche L et al. Long-term efficacy and safety results from the Phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. EHA 2024;Abstract P915.
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis.Haematologica 2024;109(7):2239-49. Abstract
Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.
Shah MR et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma: Longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 study. ASH 2024;Abstract 3369.
Usmani SZ et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial.Nat Med 2025;31(4):1195-202. Abstract
Usmani SZ et al. Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis. ASH 2024;Abstract 497.
Yong K et al. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): Overall survival analysis of a phase 3, randomised, controlled trial.Lancet Haematol 2024;11(10):e741-50. Abstract
Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
Customize the selection of first-line therapy for newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
Appreciate clinical trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory MM.
Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
Evaluate the biological rationale for and published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
Review recently presented research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential role of this form of treatment in clinical practice.
Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in relevant clinical trials.
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) CME credit is no longer available for this issue.
PRIVACY POLICY Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/MM/Presentations/CME.
CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Meletios-Athanasios (Thanos) C Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece
Robert Z Orlowski, MD, PhD Florence Maude Thomas Cancer Research Professor Department of Lymphoma and Myeloma Professor, Department of Experimental Therapeutics Vice Chair, Myeloma Translational Research Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas
Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Stock Options — Private Companies: Asylia Therapeutics Inc.
MODERATOR —Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from GSK and Sanofi.
Release date: June 2025 Expiration date: June 2026
Ailawadhi S et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses.Blood 2024;144(23):2389-401. Abstract
Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study.Blood 2025;145(3):300-10. Abstract
Bertamini L et al. Circulating tumor cells as a biomarker to identify high-risk transplant eligible myeloma patients treated with bortezomib, lenalidomide and dexamethasone with or without daratumumab during induction/consolidation, and lenalidomide with or without daratumumab during maintenance: Results from the Perseus study. ASH 2024;Abstract 487.
Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma.N Engl J Med 2025;392(2):138-49. Abstract
Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma.N Engl J Med 2025;392(18):1777-88. Abstract
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma.N Engl J Med 2024;391(5):408-21. Abstract
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(17):1597-609. Abstract
Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(5):393-407. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.
Jurgens EM et al. Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis.J Clin Oncol 2025;43(5):498-504. Abstract
Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial.Nat Med 2024;30(8):2235-41. Abstract
Mai EK et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: Final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43(11):1279-88. Abstract
Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. IMS 2024;Abstract OA-65.
Pasquini MC et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival.J Clin Oncol 2024;42(23):2757-68. Abstract
Prince HM et al. MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. ASH 2024;Abstract 4738.
Rasche L et al. Long-term efficacy and safety results from the Phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. EHA 2024;Abstract P915.
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis.Haematologica 2024;109(7):2239-49. Abstract
Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.
Shah MR et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma: Longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 study. ASH 2024;Abstract 3369.
Usmani SZ et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial.Nat Med 2025;31(4):1195-202. Abstract
Usmani SZ et al. Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis. ASH 2024;Abstract 497.
Yong K et al. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): Overall survival analysis of a phase 3, randomised, controlled trial.Lancet Haematol 2024;11(10):e741-50. Abstract
Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma
National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Professor and Chairman,
Plasma Cell Dyscrasias Unit,
Section of Hematology and Medical Oncology,
Department of Clinical Therapeutics,
School of Medicine
Faculty
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
Customize the selection of first-line therapy for newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
Appreciate clinical trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory MM.
Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
Evaluate the biological rationale for and published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
Review recently presented research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential role of this form of treatment in clinical practice.
Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in relevant clinical trials.
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC) CME credit is no longer available for this issue.
PRIVACY POLICY Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/MM/Presentations/CME.
CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Meletios-Athanasios (Thanos) C Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece
Robert Z Orlowski, MD, PhD Florence Maude Thomas Cancer Research Professor Department of Lymphoma and Myeloma Professor, Department of Experimental Therapeutics Vice Chair, Myeloma Translational Research Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas
Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Stock Options — Private Companies: Asylia Therapeutics Inc.
MODERATOR —Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from GSK and Sanofi.
Release date: June 2025 Expiration date: June 2026
Ailawadhi S et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses.Blood 2024;144(23):2389-401. Abstract
Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study.Blood 2025;145(3):300-10. Abstract
Bertamini L et al. Circulating tumor cells as a biomarker to identify high-risk transplant eligible myeloma patients treated with bortezomib, lenalidomide and dexamethasone with or without daratumumab during induction/consolidation, and lenalidomide with or without daratumumab during maintenance: Results from the Perseus study. ASH 2024;Abstract 487.
Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma.N Engl J Med 2025;392(2):138-49. Abstract
Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma.N Engl J Med 2025;392(18):1777-88. Abstract
Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma.N Engl J Med 2024;391(5):408-21. Abstract
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(17):1597-609. Abstract
Freeman CL et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Preliminary results from the IMMagine-1 trial. ASH 2024;Abstract 1031.
Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma.N Engl J Med 2024;391(5):393-407. Abstract
Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.
Jurgens EM et al. Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis.J Clin Oncol 2025;43(5):498-504. Abstract
Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial.Nat Med 2024;30(8):2235-41. Abstract
Mai EK et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: Final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2025;43(11):1279-88. Abstract
Mateos M-V et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): Phase 3 CARTITUDE-4 study update. IMS 2024;Abstract OA-65.
Pasquini MC et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival.J Clin Oncol 2024;42(23):2757-68. Abstract
Prince HM et al. MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. ASH 2024;Abstract 4738.
Rasche L et al. Long-term efficacy and safety results from the Phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. EHA 2024;Abstract P915.
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis.Haematologica 2024;109(7):2239-49. Abstract
Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.
Shah MR et al. Linvoseltamab in patients with relapsed/refractory multiple myeloma: Longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 study. ASH 2024;Abstract 3369.
Usmani SZ et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial.Nat Med 2025;31(4):1195-202. Abstract
Usmani SZ et al. Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis. ASH 2024;Abstract 497.
Yong K et al. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): Overall survival analysis of a phase 3, randomised, controlled trial.Lancet Haematol 2024;11(10):e741-50. Abstract
